Durata Therapeutics Now Covered by Analysts at Gabelli (DRTX)
Other equities research analysts have also recently issued reports about the stock. Analysts at JMP Securities reiterated an “outperform” rating on shares of Durata Therapeutics in a research note on Thursday. They now have a $22.00 price target on the stock, up previously from $19.00. Separately, analysts at Roth Capital raised their price target on shares of Durata Therapeutics from $21.00 to $24.00 in a research note on Tuesday, May 27th. They now have a “buy” rating on the stock. Finally, analysts at RBC Capital raised their price target on shares of Durata Therapeutics from $19.00 to $23.00 in a research note on Tuesday, May 27th. They now have an “outperform” rating on the stock. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $19.88.
Shares of Durata Therapeutics (NASDAQ:DRTX) opened at 16.73 on Friday. Durata Therapeutics has a 1-year low of $6.70 and a 1-year high of $17.20. The stock’s 50-day moving average is $15.55 and its 200-day moving average is $13.55. The company’s market cap is $445.7 million.
Durata Therapeutics (NASDAQ:DRTX) last announced its earnings results on Thursday, May 8th. The company reported ($0.62) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.64) by $0.02. On average, analysts predict that Durata Therapeutics will post $-2.39 earnings per share for the current fiscal year.
In other Durata Therapeutics news, CEO Paul R. Edick bought 3,000 shares of the stock in a transaction that occurred on Thursday, June 12th. The shares were purchased at an average price of $15.23 per share, for a total transaction of $45,690.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Durata Therapeutics, Inc is a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.